Rosebud Biosciences
Growing micro-organs to find new drugs
Rosebud Biosciences accelerates drug development by screening drugs against organoids (micro-organs) that have the same gene mutations as the patients. We partner with therapeutics companies to screen their drugs, and we perform our own drug discovery for rare diseases that have no existing treatments. Our organoids are also fetal-like and enable discovery of novel drug targets for pediatric diseases. This technology was validated at Stanford, published in a prestigious journal, and has already led to the discovery of a drug target in a pediatric heart disease that could not have been found using traditional disease models.
Active Founders
Kitch Wilson, Founder
Kitch is CEO and co-founder of Rosebud Biosciences. He is a Physician-Scientist (MD, PhD) with 16 years’ experience merging human induced pluripotent stem cells with genomic and molecular technologies. A Stanford-trained molecular pathologist, Kitch was an attending physician at Stanford for 6 years before cofounding Rosebud.
Evan Lyall, Founder
Evan is co-founder and CTO of Rosebud Biosciences. Evan is a Scientist-Engineer (PhD) with 10 years’ experience in advanced microscopy, machine learning, and data engineering. At UC Berkeley he studied the neural coding of perception and was part of a team that built the first bidirectional brain machine interface with proven single cell resolution. Before joining Rosebud he contracted for startups as a data and ML engineer.
Selected answers from Rosebud Biosciences's original YC application for the W22 Batch
Describe what your company does in 50 characters or less.
Drug discovery for pediatric genetic diseases
How long have each of you been working on this? How much of that has been full-time? Please explain.
Kitch (CEO) began working full-time on the business plan and ideas for Rosebud’s platform technology in June 2020. Evan joined full-time as cofounder and CTO in January 2021.
YC W22 Demo Day Video